Research & KnowledgeEvent: September 4, 2026
Curi Bio published longitudinal transgene expression data of characterizing capsid transduction efficiency in 96 human iPSC-derived engineered skeletal muscle tissues and a panel of in vivo validated myotropic AAV capsids from Dyno Therapeutics.
Published
Signal category
Research & Knowledge
Quote
“One plate, 96 human iPSC-derived engineered skeletal muscle tissues, and a panel of in vivo validated myotropic AAV capsids from Dyno Therapeutics.”
— Curi Bio team
Company
Curi Bio
Human Data for Next Generation Medicines
- Industry
- Biotechnology Research
- Location
- Seattle, US
- Company size
- 56 employees
"Human Data for Next Generation Medicines" Curi Bio unlocks novel workflows and critical human data to inform R&D decision-making. Through an integrated platform featuring advanced 3D tissue models of disease, biosystems enabling clinically relevant functional analyses, and AI/ML-enabled insights, Curi Bio merges functional and analytical assessments for drug safety, efficacy, and potency
Founded 2015